Studies of Hereditary Neurological Disease: Disease Mechanisms

$1,622,500ZIAFY2010NSNIH

National Institute Of Neurological Disorders And Stroke

Investigators

Linked publications & trials

Paper 36746939 Paper 35907632 Paper 35867854 Paper 34417184 Paper 34131327 Paper 34059824 Paper 33979606 Paper 33646171 Paper 33575118 Paper 33554969 Paper 32788345 Paper 32773451 Paper 32641584 Paper 32623324 Paper 32056234 Paper 31957062 Paper 31942037 Paper 31887286 Paper 31028127 Paper 30615147 Paper 30148479 Paper 30108179 Paper 29924488 Paper 29725819 Paper 29560381 Paper 29478602 Paper 29400714 Paper 29395064 Paper 29353237 Paper 29142082 Paper 28986271 Paper 28450545 Paper 28402699 Paper 28003546 Paper 27882347 Paper 27312068 Paper 26962150 Paper 26863047 Paper 26792401 Paper 26755334 Paper 26547319 Paper 25840413 Paper 25569348 Paper 24999486 Paper 24925468 Paper 24814856 Paper 24807208 Paper 24760765 Paper 24742452 Paper 24668811 Paper 24561252 Paper 24515897 Paper 23678877 Paper 23615451 Paper 22952056 Paper 22798624 Paper 22668795 Paper 22327341 Paper 22144914 Paper 21693563 Paper 21562249 Paper 20863580 Paper 20336775 Paper 20152552 Paper 20090835 Paper 20037586 Paper 19679072 Paper 19297400 Paper 19228953 Paper 19158308 Paper 19103745 Paper 18824496 Paper 18562277 Paper 17035524

Abstract

The purpose of this research program is to investigate the mechanisms of hereditary neurological diseases, with the ultimate intent of developing effective treatments for these disorders. The research focuses on three specific motor neuron diseases: autosomal recessive spinal muscular atrophy (SMA) due to deficiency of the protein SMN, X-linked spinal and bulbar muscular atrophy (SBMA) due to polyglutamine expansion in the androgen receptor, and distal spinal muscular atrophy/Charcot-Marie-Tooth disease type 2D (CMT2D) caused by mutations in tRNA synthetase. Specific research accomplishments in the past year include the following: (1) characterization of the role of IGF-1 and Akt in a cell culture model of SBMA, (2) evaluation of the efficacy of histone deacetylase and proteasome inhibitor treatment in a mouse model of SMA, (3) studies of the disease mechanisms of CMT2D and other hereditary forms of neuropathy and distal spinal muscular atrophy.

View original record on NIH RePORTER →